Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial

Registros relacionados

• Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
  por: Mayne, K, et al.
  Publicado em: (2024)
• Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
  por: Staplin, N, et al.
  Publicado em: (2023)
• Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
  por: Mayne, KM, et al.
  Publicado em: (2024)
• Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
  por: Nangaku, M, et al.
  Publicado em: (2024)
• Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
  por: Staplin, N, et al.
  Publicado em: (2023)